Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer

Oncology Reports

Volumn 17, Issue 6, 2007, Pages 1469-1474

  Sonoda, Teppei ^a   Sugimura, Kazunobu ^a   Ikemoto, Shin Ichi ^a   Kawashima, Hidenori ^a   Nakatani, Tatsuya ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bacillus Calmette Guerin; Bladder cancer; Intravesical instillation; Natural killer cells

Indexed keywords

BCG VACCINE;

ANIMAL; ARTICLE; BLADDER TUMOR; C57BL MOUSE; CARCINOMA; CYTOTOXICITY; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MALE; MICROBIOLOGY; MOUSE; NATURAL KILLER CELL; TUMOR CELL LINE;

ANIMALS; BCG VACCINE; CARCINOMA; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; URINARY BLADDER NEOPLASMS;

EID: 34548019748     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.6.1469     Document Type: Article

References (20)

1. Lamm DL, Riggs DR, Traynelis CL and Nseyo UO: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153: 1444-1450, 1995.
2. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK and Bijnens L: A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 156: 1934-1940, 1996.
3. Morales A, Eidinger D and Bruce AW: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116: 180-183, 1976.
4. Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE and Rowland RG: Bladder cancer clinical guidelines panel summary report on the management of non-muscle invasive bladder cancer (stages Ta, T1 and TIS). J Urol 162: 1697-1701, 1999. (Pubitemid 29474702)
5. Herr HW, Schwalb DM, Zhang ZF, Sogani PC, Fair WR, Whitmore WF Jr and Oettgen HF: Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 13: 1404-1408, 1995.
6. Ratliff TL: Role of the immune response in BCG for bladder cancer. Eur Urol 21 (suppl 2): S17-S21, 1992.
7. Alexandroff AB, Jackson AM, O'Donnell MA and James K: BCG immunotherapy of bladder cancer: 20 years on. Lancet 353: 1689-1694, 1999. (Pubitemid 29224536)
8. Rubenstein M, Muchnik S, Chet M, Shaw MW, McKiel CF and Guinan PD: Tumor infiltrating lymphocytes: the effect of bacillus Calmette Guerin on helper/suppressor-T cell ratios of treated and untreated tumors. J Urol 146: 1650-1653, 1991.
9. Leong AS, Wannakrairot P, Jose J and Milios J: Bacillus Calmette- Guerin-treated superficial bladder cancer: correlation of morphology with immunophenotyping. J Pathol 162: 35-41, 1990. (Pubitemid 20291447)
10. Bohle A, Gerdes J, Ulmer AJ, Hofstetter AG and Flad HD: Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144: 53-58, 1990. (Pubitemid 20221267)
11. El-Demiry MI, Smith G, Ritchie AW, James K, Cumming JA, Hargreave TB and Chisholm GD: Local immune responses after intravesical BCG treatment for carcinoma in situ. Br J Urol 60: 543-548, 1987. (Pubitemid 18002600)
12. Fleischmann JD, Toossi Z, Ellner JJ, Wentworth DB, Ratliff TL and Imbembo AL: Urinary interleukins in patients receiving intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. Cancer 64: 1447-1454, 1989. (Pubitemid 19238960)
13. Prescott S, James K, Hargreave TB, Chisholm GD and Smyth JF: Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 144: 1248-1251, 1990. (Pubitemid 20388099)
14. Sidransky D, Frost P, von Eschenbach A, Oyasu R, Preisinger AC and Vogelstein B: Clonal origin bladder cancer. N Engl J Med 326: 737-740, 1992.
15. Jones TD, Wang M, Eble JN, et al: Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 11: 6512-6519, 2005. (Pubitemid 41338989)
16. Reichert DF and Lamm DL: Long term protection in bladder cancer following intralesional immunotherapy. J Urol 132: 570-573, 1984. (Pubitemid 14026175)
17. Davis JW, Sheth SI, Doviak MJ and Schellhammer PF: Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J Urol 167: 494-500, 2002. (Pubitemid 34074513)
18. Hudson MA and Herr HW: Carcinoma in situ of the bladder. J Urol 153: 564-572, 1995.
19. Van Furth R: Mycobacteria and macrophage activation. Res Microbiol 141: 256-261, 1990.
20. Dannenberg AM Jr: Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis. Immunobiology 191: 461-473, 1994.